Get the Stockscreener App
9.47
4.44%
-0.44
Sagimet Biosciences Inc stock is traded at $9.47, with a volume of 889.56K.
It is down -4.44% in the last 24 hours and up +52.99% over the past month.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$9.91
Open:
$9.76
24h Volume:
889.56K
Relative Volume:
0.70
Market Cap:
$191.24M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-7.9848
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
+14.79%
1M Performance:
+52.99%
6M Performance:
+82.82%
1Y Performance:
+189.60%
1-Day Range:
$9.32
$9.92
1-Week Range:
$7.93
$9.98
52-Week Range:
$1.73
$10.43
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
9.47 | 191.24M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know - MSN
Sagimet Biosciences’ SWOT analysis: promising FASN inhibitor stock faces funding hurdles By Investing.com - Investing.com South Africa
Sagimet Biosciences’ SWOT analysis: promising FASN inhibitor stock faces funding hurdles - Investing.com
Sagimet stock holds steady as JMP reiterates $31 price target By Investing.com - Investing.com Nigeria
Sagimet Biosciences Inc: Analyzing SGMT Stock Trends - investchronicle.com
Two Sigma Investments LP Trims Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Sagimet Biosciences updates executive compensation By Investing.com - Investing.com South Africa
Sagimet Biosciences updates executive compensation - Investing.com
Sagimet Biosciences Elects New Directors at Annual Meeting - TipRanks
Sagimet Biosciences to Host Virtual KOL Event, “A New - GlobeNewswire
Sagimet Biosciences to host KOL event on denifanstat results - TipRanks
Sagimet Biosciences (SGMT) to Highlight Positive Phase 3 Acne Treatment Results | SGMT Stock News - GuruFocus
Sagimet Biosciences to Host Virtual KOL Event, 'A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025 - The Manila Times
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025 - GlobeNewswire
Breakthrough Phase 3 Results: Novel Oral Acne Drug Shows Promise for 50M US Patients - Stock Titan
Analysts Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $23.17 - Defense World
Squarepoint Ops LLC Grows Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences (NASDAQ:SGMT) Stock Price Expected to Rise, Jones Trading Analyst Says - Defense World
Sagimet Biosciences (SGMT) Price Target Raised by Jones Trading - GuruFocus
Sagimet Biosciences (SGMT) Price Target Raised by Jones Trading | SGMT Stock News - GuruFocus
Sagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug Results - MSN
Sagimet Biosciences price target raised to $27 from $15 at JonesResearch - TipRanks
Sagimet Biosciences (SGMT) Target Price Raised to $27 by Analyst | SGMT Stock News - GuruFocus
Uncovering Hidden Gems: Penny Stocks To Consider In June 2025 - Yahoo Finance
Jane Street Group LLC Purchases New Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Promising Potential of Sagimet Biosciences: Buy Rating Affirmed by Positive Phase 3 Trial Results and Strategic Advancements - TipRanks
Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567 (SGMT) - Seeking Alpha
leerink partners maintains outperform rating on sagimet stock By Investing.com - Investing.com Canada
Sagimet Biosciences (SGMT) Surges on Successful Acne Drug Trial in China - GuruFocus
Sagimet partner Ascletis announces significant Phase III acne data - The Pharma Letter
Sector Update: Health Care - MarketScreener
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Acne Trial In China, Stock Jumps - Benzinga
leerink partners maintains outperform rating on sagimet stock - Investing.com
Sagimet Biosciences shares soar on positive acne treatment trial results By Investing.com - Investing.com South Africa
Sagimet Biosciences shares soar on positive acne treatment trial results - Investing.com
Sagimet stock climbs on acne trial data (SGMT:NASDAQ) - Seeking Alpha
Sagimet Biosciences Announces Phase 3 Trial Success - TipRanks
Sagimet Biosciences Announces Positive Phase 3 Results for - GlobeNewswire
Sagimet Biosciences Says Acne Vulgaris Treatment Meets Phase 3 Trial Primary, Secondary Endpoints - marketscreener.com
Sagimet Biosciences Announces Positive Phase 3 Results For Denifanstat - marketscreener.com
Sagimet Biosciences Reports Successful Phase 3 Results for Denifanstat in Moderate to Severe Acne and Initiates Phase 1 Trial for TVB-3567 - Nasdaq
Breakthrough Acne Treatment Achieves Phase 3 Success: First New Oral Drug Mechanism in 40 Years Shows Promise - Stock Titan
Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment - Investing.com Australia
Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment By Investing.com - Investing.com Nigeria
Sagimet Biosciences to host KOL event on denifanstat, resmetirom - TipRanks
Sagimet Biosciences (SGMT) to Host Key Opinion Leader Event on I - GuruFocus
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating - GlobeNewswire
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sagimet Biosciences Inc Stock (SGMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Martins Eduardo Bruno | Chief Medical Officer |
Jul 19 '24 |
Sale |
3.10 |
8,357 |
25,910 |
81,213 |
| Rozek Elizabeth | General Counsel and CCO |
Jul 19 '24 |
Sale |
3.10 |
10,914 |
33,830 |
160,506 |
| Kemble George | Executive Chairman |
Jul 19 '24 |
Sale |
3.10 |
14,062 |
43,605 |
142,318 |
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):